Navigation Links
Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
Date:5/3/2012

SEATTLE, May 3, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has identified compounds that functionally interact with each of four additional orphan G protein-coupled receptors (GPCRs). Without compounds that functionally interact with orphan GPCRs, developing drugs targeting those receptors is extremely difficult. Omeros has now unlocked 37 of them, representing over 45 percent of the Class A orphan GPCRs. There are approximately 120 orphan GPCRs and Omeros expects to unlock a large percentage of them, focusing first on Class A orphan GPCRs.

The four additional orphan GPCRs unlocked by Omeros are GPR83, GPR150, GPR151 and GPR183. GPR83 has been implicated in memory, stress and control of emotions and is also associated with autoimmune and inflammatory diseases. GPR150 is linked to ovarian cancer, while GPR151 is involved with cognition. GPR183 is an important component of the immune system and plays a central role in controlling B-cell migration and T-cell-dependent antibody production. Omeros is in the process of filing broad patent applications around its unlocked orphan GPCRs and compound optimization efforts are in progress.

"Our GPCR program currently remains focused on rapidly unlocking orphan receptors and uniquely elucidating their respective signaling profiles, and our successes continue to mount," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "The data generated by this approach enable medicinal chemistry to develop potential therapeutics and feed directly into our primary patent objective – to exclusively control each receptor that we unlock together with the compounds that functionally interact with it."

Ongoing GPCR Program

Omeros is screening orphan GPCRs against its small-molecule chemical libraries using its proprietary, high-throughput cellular redist
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 Today ... solutions, introduced the next-generation of its Employer ... allows health plans to provide their employer groups ... health factors, medical and prescription drug claims, network ... (Logo: http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer ...
(Date:6/19/2013)... 2013  It may seem like an odd pairing: an ... But these were two of the most talked about topics ... Meeting & Expo that just convened in San ... by some of the top internal medicine experts in the ... research that can not only save lives, but help people ...
(Date:6/18/2013)...  Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT ), ... and commercialization of novel bile acid therapeutics to treat ... underwritten public offering of 1,730,000 shares of its common ... share.  In addition, Intercept has granted the underwriters a ... shares of common stock. All of the ...
Breaking Medicine Technology:MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 3"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 4Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... Contributing Editor Human papillomaviruses (HPVs) are small, closed ... nucleic acid sequence homology rather than serologic reactivity. ... transmitted pathogens. Of the approximately 50 anogenital ... and intermediate risk types detected in anogenital cancer ...
... Londe, M.D. Contributing Editor Clinical guidelines from the disciplines ... emphasized the importance of cardiac markers in diagnosing or ... cardiac troponins is especially useful in the large fraction ... have negative 12-lead EKGs. About 30% of patients ...
Cached Medicine Technology:Testing for Human Papillomavirus 2Testing for Human Papillomavirus 3Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results 2Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results 3
(Date:6/19/2013)... Moffitt Cancer Center and colleagues at Louisiana State University ... that require immediate therapy. It relies on understanding the ... is to better predict a prostate cancer,s aggressiveness to ... published in the online journal PLOS ONE ... accounts for 20 percent of all cancers and 9 ...
(Date:6/19/2013)... Brightree LLC , the leading ... for the post-acute care industry, has been ranked for the ... Healthcare Informatics 100 (HCI 100) list. This prestigious list ... in terms of revenue during the last fiscal year. Since ... 85% annually, and the company has built its organization to ...
(Date:6/19/2013)... Kansas City, MO (PRWEB) June 19, 2013 Kansas ... as part of Main Street Day . A section of ... and pedestrian traffic during the afternoon of the event. The ... to host the event, which will help Kansas City join the ... have used Ciclovia as a tool to foster community vibrancy and ...
(Date:6/19/2013)... Louis, MO (PRWEB) June 19, 2013 ... organization, partnered with ARAMARK Healthcare Technologies to help ... management plan with savings of more than 17 ... and maintenance service expenditures. , “Driving economies of ... top medical equipment management challenges facing multi-site providers,” ...
(Date:6/19/2013)... Crawley, UK-- New data, published today in ... Britain are experiencing less sex, and less satisfying ... counterparts1, because they are considerably less likely to ... called vaginal atrophy1. , The first-of-its-kind study, called ... Relationships (CLOSER) study, showed that British post-menopausal women ...
Breaking Medicine News(10 mins):Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 2Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 3Health News:Amerinet Partners with ARAMARK Healthcare Technologies to Help Pacific Medical Centers Save 17 Percent and Better Manage System-Wide Equipment Program 2Health News:British women 50 percent less likley to recieve treatment for common menopausal symptoms 2
... E. coli infection from tainted spinach. E. coli experts like ... University// of British Columbia in Canada, can explain how the ... Finlay's lab determined the molecular structure of E. coli, information ... as well as a vaccine for cattle, because E. coli ...
... seem to be at significantly greater risk of developing ... of print in the journal Gut. ,The ... 1250 of whom were identical. The twins completed a ... ever had IBS. ,This information was then ...
... agent involved in food poisoning and account for hundreds ... invades by stealth and hides from macrophages before entering ... macrophages are the cells meant to detect such bacteria. ... turning predator cells to prey complicit in promoting infection, ...
... up to 23,000 junior doctor training posts in the UK next ... [JDC], Dr Tom Dolphin, said ,"The BMA is delighted ... number of training posts, and this goes a long way towards ... concerned about what happens to those who do not get into ...
... The injection is safe when performed by physicians experienced ... and sustained, according to the one-year, multi-center cohort study. ... study, the mean pain score on a 10-point visual ... 1.4 at two weeks, 0.5 at 24 weeks, and ...
... officials have reported the death of two women after consumption ... had previous history of health problems.//, ,Agriculture Commissioner Tommy ... they did something they shouldn’t have done and they lost ... a major health threat. ,The DeKalb Farmers’ Market ...
Cached Medicine News:Health News:Restricted Fetal Growth Increases Risk of Irritable Bowel Syndrome 2Health News:Salmonella Bacteria Are Deceptive 2Health News:Sacroplasty Safe and Effective to Reduce Low Back Pain 2Health News:Sacroplasty Safe and Effective to Reduce Low Back Pain 3
Use Streck-Sheath to count and classify white blood cells on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf life is two years from date of manufacture...
A lytic reagent manufactured for the simultaneous quantitative determinations of hemoglobin and white blood cells. Streck-Lysing Agent III is for use on the Abbott CELL-DYN® 1400 and 1600. The sh...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
Medicine Products: